Anzeige
Meldung des Tages: Drohnen statt Panzer: Beginnt hier der nächste Milliarden-Superzyklus?

Armata Pharmaceuticals News

Aktie
WKN:  A2PKLC ISIN:  US04216R1023 US-Symbol:  ARMP Branche:  Biotechnologie Land:  USA
7,20 €
+0,15 €
+2,13%
22:43:24 Uhr
Depot/Watchlist
Marktkapitalisierung *
202,23 Mio. €
Streubesitz
28,77%
KGV
-4,13
Index-Zuordnung
-

Armata Pharmaceuticals News

19.03.26 - PR Newswire
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update PR Newswire
23.02.26 - PR Newswire
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 PR Newswire
13.01.26 - PR Newswire
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./ PR Newswire
18.11.25 - PR Newswire
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST PR Newswire
12.11.25 - PR Newswire
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update PR Newswire
10.11.25 - PR Newswire
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Armata Pharmaceuticals Announces Formal Commissioning of State-​of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California PR Newswire
22.10.25 - PR Newswire
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-​Breaking Oral ...
14.10.25 - PR Newswire
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
Armata Pharmaceuticals to Present Late-​Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ PR Newswire
08.09.25 - PR Newswire
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology PR Newswire
04.09.25 - PR Newswire
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
12.08.25 - PR Newswire
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update PR Newswire
19.05.25 - PR Newswire
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus ...
14.05.25 - PR Newswire
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update PR Newswire
01.05.25 - PR Newswire
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-​Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 ...
20.03.25 - PR Newswire
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update PR Newswire
12.03.25 - PR Newswire
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva PR Newswire
11.03.25 - PR Newswire
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit PR Newswire
19.12.24 - PR Newswire
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-​Cystic Fibrosis Bronchiectasis Subjects with Chronic ...
19.11.24 - PR Newswire
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting PR Newswire
12.11.24 - PR Newswire
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus ...

Newssuche

Videos

newspaper
19.03.26
COUNTER HUNTER Strategie Einführung
Live-​Seminar am 29.3. ab 14 Uhr! Wie immer wird die Schulung auch aufgezeichnet und allen ... Mehr »